Genome-wide transcriptional sequencing identifies novel mutations in metabolic genes in human hepatocellular carcinoma.

Daoud M Meerzaman,Chunhua Yan,Qing-Rong Chen,Michael N Edmonson,Carl F Schaefer,Robert J Clifford,Barbara K Dunn,Li Dong,Richard P Finney,Constance M Cultraro,Ying Hu,Zhihui Yang,Cu V Nguyen,Jenny M Kelley,Shuang Cai,Hongen Zhang,Jinghui Zhang,Rebecca Wilson,Lauren Messmer,Young-Hwa Chung,Jeong A Kim,Neung Hwa Park,Myung-Soo Lyu,Il Han Song,George Komatsoulis,Kenneth H Buetow

2014-01-01

Cancer Genomics & Proteomics

Abstract:We report on next-generation transcriptome sequencing results of three human hepatocellular carcinoma tumor/tumor-adjacent pairs. This analysis robustly examined similar to 12,000 genes for both expression differences and molecular alterations. We observed 4,513 and 1,182 genes demonstrating 2-fold or greater increase or decrease in expression relative to their normal, respectively. Network analysis of expression data identified the Aurora B signaling, FOXM1 transcription factor network and Wnt signaling pathways pairs being altered in HCC. We validated as differential gene expression findings in a large data set containing of 434 liver normal/tumor sample pairs. In addition to known driver mutations in TP53 and CTNNB1, our mutation analysis identified non-synonymous mutations in genes implicated in metabolic diseases, i.e. diabetes and obesity: IRS1, HMGCS1, ATP8B1, PRMT6 and CLU, suggesting a common molecular etiology for HCC of alternative pathogenic origin.